GHENT, Belgium, March 14, 2014 /PRNewswire/ -- ActoGeniX NV, creator of ActoBiotics, announced today that Bernard Coulie, Chief Executive Officer, will present a company overview at the 21st Annual Future Leaders in the Biotech Industry Conference at 1:30pm ET on Friday, March 28, 2014, at the Millennium Broadway Hotel in New York City.
A live webcast of the presentation will be available at the following link: https://www.webcaster4.com/Webcast/Page/392/3742 and on the Company's website in the News & Events section, at http://www.actogenix.com/news/news-events/. A replay will be available after the presentation and will be archived on the company's website for one year following the live event.
ActoGeniX is a biopharmaceutical company focused on the development and commercialization of ActoBiotics, a novel class of orally available biopharmaceuticals for the targeted treatment of severe diseases with a high medical need. ActoBiotics represent a novel concept for oral administration of therapeutic proteins, and are designed to be safer and more effective than injectable biopharmaceuticals. ActoBiotics can deliver a wide range of therapeutic peptides and proteins, including cytokines, enzymes, hormones and monoclonal antibodies.
ActoGeniX has confirmed the broad applicability of ActoBiotics and its proprietary technology platform for a wide range of diseases, including oral, gastrointestinal, metabolic, immune, and allergic diseases.
ActoGeniX was founded in 2006 as a spin-off from VIB and Ghent University. The Company is headquartered in Ghent (Belgium) and employs 22 staff. ActoGeniX raised 46 million Euro (approximately 60 million US$) in 3 equity financing rounds from a consortium of leading life sciences investors such as Gimv, Biotech Fund Flanders, Baekeland Fund, Biovest, Saffelberg Investments (Belgium), Life Sciences Partners, Aescap Venture (The Netherlands) and Ventech (France).
ActoGeniX has a strong and broad intellectual property position with a patent estate encompassing more than 20 distinct patent families. With broad patent claims already granted in major territories like the US, Europe, Japan, and China, ActoGeniX is uniquely positioned to successfully exploit the commercial potential of its promising ActoBiotics. For additional information about ActoGeniX, visit the company's website at http://www.actogenix.com